European pharma chiefs warn continent losing drug innovation race to US, China

Chairs of nine major European drugmakers, including AstraZeneca, GSK, and Novo Nordisk, wrote to national leaders warning that Europe is falling behind the US and China in drug development and investment attraction. The letter calls for policy action to safeguard the industry's future, signaling growing concern over competitiveness. The outcome depends on whether governments respond with concrete measures.